Does cabergoline improve cognition and attention more than placebo in healthy volunteers and what does this tell us about mechanisms of attention?

A randomised controlled trial comparing the effects of cabergoline vs placebo on executive control in healthy male volunteers

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12611000604909

Enrollment

Registered

2011-06-10

Start date

2011-06-20

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Cognitive control and spatial attention are skills that allows us to interpret and act in our environment. Although these skills are important, little is understood about the neurochemical processes that are important to cognitive control and spatial attention. This study will allow us to assess the importance of different brain chemicals in contributing to spatial attention and cognitive function.

Interventions

A single dose of cabergoline (oral capsule containing 1.25mg) (1-2 week washout period between conditions)

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

Male

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers Aged 18 -40 years Male

Exclusion criteria

Current psychiatric or neurological illness Current use of psychotropic medication CUrrent substance use or dependence Medical illness that is a contraindication for cabergoline use

Outcome results